

BIOTECH CAPITAL TO TRADE AS “BTC HEALTH”

Biotech Capital Limited (ASX: BTC) wishes to announce that it has registered the trading name of BTC Health with the Australian Securities and Investments Commission (ASIC) and also made a trademark application to IP Australia. Effective today, the Company will commence trading as BTC Health.

Shareholder approval is required to change the Company name to “BTC Health Limited”. The use of the trading name is an interim measure and shareholder approval will be sought for the name change when convenient to do so at a future shareholder meeting.

About Biotech Capital Limited

Biotech Capital is a listed entity on the ASX and is a Pooled Development Fund, registered under the Pooled Development Funds Act 1992. The company’s strategy is to make active investments in life science businesses and late-stage product development opportunities that will benefit from greater access to development capital. The company has the longer-term objective of building a group of complimentary businesses that are entrepreneurial, innovative, globally focused and when operating together have the ability to generate better health outcomes and add value for its shareholders.

Under the Pooled Development Funds Act 1992, shareholders are entitled to concessionary tax treatment in Australia for income and capital gains derived in connection with their shareholding. Gains realised on the disposal of shares will not be included in an investor’s assessable income in Australia. An investor will not be entitled to any deduction or capital loss on the sale of shares. Unfranked dividends received by an Australian resident will be exempt from tax. Franked dividends will also be exempt from tax unless the shareholder elects to be taxed. An Australian corporate tax entity may credit its franking account (with franking credits attaching to a franked dividend), regardless of whether it has elected to treat the dividend as exempt or assessable income. Dividends paid to non-residents will not be subject to withholding tax. A shareholder or prospective shareholder should obtain their own tax advice rather than relying on this summary.

Forward-looking Statements

This ASX-announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Biotech Capital to be materially different from the statements in this announcement.

For more information, please contact:

Dr. Richard Treagus, Executive Chairman
rtreagus@biotechcapital.com.au +61 417 520 509